ID   Ishikawa 3-H-12
AC   CVCL_D199
SY   Ishikawa-3H-12; Ishikawa-3H12; Ishikawa 3H12; Ishikawa 3 H 12; Ishikawa3-H-12; Ishikawa clone 3-H-12; Ishikawa-H-12
DR   BTO; BTO:0006568
DR   CLO; CLO_0037230
DR   cancercelllines; CVCL_D199
DR   Cosmic; 871553
DR   Cosmic; 889119
DR   Cosmic; 1007163
DR   Cosmic; 1066223
DR   Cosmic; 1223489
DR   JCRB; JCRB1505
DR   Wikidata; Q54898297
RX   DOI=10.1007/978-4-431-53981-0_2;
RX   PubMed=9183638;
RX   PubMed=22710073;
CC   Population: Japanese.
CC   Doubling time: 24.0 hours (PubMed=9183638).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): JCRB
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12,13
ST   D16S539: 9
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   TH01: 9,10
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2529 ! Ishikawa
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 17
//
RX   DOI=10.1007/978-4-431-53981-0_2;
RA   Nishida M.;
RT   "Ishikawa cells: opening of in vitro hormone research on endometrial
RT   carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.35-58; Springer; Tokyo (2003).
//
RX   PubMed=9183638;
RA   Nishida M., Kasahara K., Oki A., Satoh T., Arai Y., Kubo T.;
RT   "Establishment of eighteen clones of Ishikawa cells.";
RL   Hum. Cell 9:109-116(1996).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//